期刊
JOURNAL OF HEMATOLOGY & ONCOLOGY
卷 8, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s13045-015-0195-4
关键词
-
资金
- Shaoxing People's Hospital, Zhejiang Province, China
- Henan Provincial Grant for Overseas Research for Young Leaders of Medical Technology [2014041]
- Division of Hematology and Oncology, New York Medical College, USA
- Natural Science Foundation of China (NSFC) [81201793]
Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor (e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/refractory precursor B cell acute lymphoid leukemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
